A detailed history of Victory Capital Management Inc transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 313,257 shares of IDYA stock, worth $8.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
313,257
Previous 316,105 0.9%
Holding current value
$8.14 Million
Previous $11.1 Million 10.59%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$30.37 - $43.05 $86,493 - $122,606
-2,848 Reduced 0.9%
313,257 $9.92 Million
Q2 2024

Aug 05, 2024

BUY
$34.37 - $43.46 $1.02 Million - $1.29 Million
29,600 Added 10.33%
316,105 $11.1 Million
Q1 2024

May 03, 2024

SELL
$34.2 - $47.13 $2.05 Million - $2.83 Million
-59,985 Reduced 17.31%
286,505 $12.6 Million
Q4 2023

Feb 05, 2024

BUY
$24.59 - $35.83 $8.52 Million - $12.4 Million
346,490 New
346,490 $12.3 Million
Q1 2023

May 02, 2023

BUY
$13.49 - $18.72 $414,143 - $574,704
30,700 New
30,700 $421,000
Q2 2022

Aug 01, 2022

SELL
$8.28 - $13.88 $103,806 - $174,013
-12,537 Reduced 35.2%
23,083 $319,000
Q1 2022

May 04, 2022

BUY
$11.18 - $24.02 $210,094 - $451,383
18,792 Added 111.67%
35,620 $342,000
Q4 2021

Feb 07, 2022

BUY
$20.95 - $26.88 $352,546 - $452,336
16,828 New
16,828 $398,000
Q2 2020

Aug 07, 2020

SELL
$3.59 - $18.57 $7,029 - $36,360
-1,958 Closed
0 $0
Q1 2020

May 04, 2020

BUY
$3.03 - $10.58 $1,348 - $4,708
445 Added 29.41%
1,958 $8,000
Q4 2019

Feb 04, 2020

SELL
$5.34 - $9.09 $775,725 - $1.32 Million
-145,267 Reduced 98.97%
1,513 $13,000
Q3 2019

Nov 12, 2019

BUY
$6.06 - $10.91 $5,454 - $9,819
900 Added 0.62%
146,780 $1.32 Million
Q2 2019

Aug 15, 2019

BUY
$9.58 - $11.95 $1.4 Million - $1.74 Million
145,880 New
145,880 $1.45 Million

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.25B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.